3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
Home-Grown Partnership Pays Dividends
Executive Summary
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
You may also be interested in...
Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
AZ, Junshi Part Ways Amid China IO Commercial Struggle
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.